Skip to main content
SpringerLink
Log in

Multi-panel assay of serum autoantibodies in colorectal cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%. Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer.

Methods

Autoantibodies against 17 tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, NY-ESO-1, p90, Sui1, HSP40, CyclinB1, HCC-22-5, c-myc, PrxVI, VEGF, HCA25a, p62, and Annexin II) were evaluated in 279 patients with colorectal cancer and 74 healthy controls. Cutoff values were fixed at mean + 3 standard deviations of serum titers in healthy controls.

Results

Autoantibodies with the highest positive rates were p53 (20%), RalA (14%), HSP70 (12%), and Galectin1 (11%). Combination assays using multiple autoantibodies increased the positive rates based on the number of autoantibodies used. Positive rates of 56, 62, 66, 71, and 73% were obtained with 6, 9, 11, 14, and 17 antibodies, respectively, for the overall disease. Moreover, these autoantibodies showed relatively high positive rates even during stage 0/I disease (55 and 70% with 6 and 17 antibodies, respectively).

Conclusion

The measurement of set of 17 autoantibodies allowed autoantibody profiling in patients with colorectal cancer. The combination assay of six tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, and NY-ESO-1) achieved a positive rate of 56%. Such high positive rates will be helpful for detecting colorectal cancer regardless of tumor stages.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Das V, Kalita J, Pal M (2017) Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 87:8–19

    Article  CAS  Google Scholar 

  2. Suzuki T, Shimada H, Ushigome M et al (2016) Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol 9(2):55–58

    Article  Google Scholar 

  3. Hoshino I, Nagata M, Takiguchi N et al (2017) Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci 108:308–315

    Article  CAS  Google Scholar 

  4. Ochiai H, Ohishi T, Osumi K et al (2012) Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today 42:164–168

    Article  CAS  Google Scholar 

  5. Yamaguchi T, Takii Y, Maruyama S (2014) Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today 44:1529–1535

    Article  CAS  Google Scholar 

  6. Li Y, Karjalainen A, Koskinen H et al (2005) p53 autoantibodies predict subsequent development of cancer. Int J Cancer 114:157–160

    Article  CAS  Google Scholar 

  7. Trivers GE, De Benedetti VM, Cawley HL et al (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2:1767–1775

    CAS  PubMed  Google Scholar 

  8. Saito F, Shimada H, Ogata H et al (2017) Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody. Esophagus 1:1–4

    Google Scholar 

  9. Xu YW, Peng YH, Chen B et al (2014) Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol 109(1):36–45

    Article  CAS  Google Scholar 

  10. Lin LH, Xu YW, Huang LS et al (2017) Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clin Proteomics 1(14):6

    Article  Google Scholar 

  11. Chen H, Werner S, Butt J et al (2016) Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget 29(7):16420–16432

    Google Scholar 

  12. Negm OH, Hamed MR, Schoen RE et al (2016) Human blood autoantibodies in the detection of colorectal cancer. PLoS One 11(7):e0156971

    Article  Google Scholar 

  13. Okada R, Shimada H, Tagawa M et al (2017) Profiling of serum autoantibodies in Japanese patients with hepatocellular carcinoma. Toho J Med 3(3):84–92

    Google Scholar 

  14. Nanami T, Shimada H, Yajima S et al (2016) Clinical significance of serum autoantibodies against Ras-like GTPases RalA in patients with esophageal squamous cell carcinoma. Esophagus 13:167–172

    Article  Google Scholar 

  15. Shiratori F, Shimada H, Nagata M et al (2016) Serum galectin-1 autoantibodies in patients with hepatocellular carcinoma. Toho J Med 2:67–72

    Google Scholar 

  16. Oshima Y, Shimada H, Yajima S et al (2016) NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol 51:30–34

    Article  CAS  Google Scholar 

  17. Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York

    Google Scholar 

  18. Zhang JY, Casiano CA, Peng XX et al (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136–143

    CAS  PubMed  Google Scholar 

  19. Boyle P, Chapman CJ, Holdenrieder S et al (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22:383–389

    Article  CAS  Google Scholar 

  20. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’for medical statistics. Bone Marrow Transplant 48:452–458

    Article  CAS  Google Scholar 

  21. Shimada H, Hoshino T, Okazumi S et al (2002) Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of esophageal squamous cell carcinoma. Br J Cancer 86:552–557

    Article  CAS  Google Scholar 

  22. Tokunaga R, Sakamoto Y, Nakagawa et al (2017) The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surg Today 47:636–642

    Article  CAS  Google Scholar 

  23. Shimada H, Shiratori T, Takeda A et al (2009) Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 33:272–277

    Article  Google Scholar 

Download references

Acknowledgements

Junichi Koike received research grant from JSPS KAKENHI Grant Number JP26462029.

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan

    Mitsunori Ushigome, Junichi Koike, Kimihiko Funahashi & Hideaki Shimada

  2. Division of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan

    Yoshihiro Nabeya, Hiroaki Soda & Nobuhiro Takiguchi

  3. Medical & Biological Laboratories Co., Ltd, 4-5-3 Sakae, Naka-ku, Nagoya, 460-0008, Japan

    Akiko Kuwajima

  4. Division of Pathology and Cell Therapy, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan

    Masatoshi Tagawa

  5. Department of Laboratory Medicine and Division of Clinical Genetics and Proteomics, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

    Kazuyuki Matsushita

Authors
  1. Mitsunori Ushigome
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Nabeya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroaki Soda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuhiro Takiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akiko Kuwajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masatoshi Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuyuki Matsushita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junichi Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kimihiko Funahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Shimada.

Ethics declarations

Conflict of interest

Hideaki Shimada received research Grants from Medical & Biological Laboratories Co., Ltd., Nagoya, Japan. Akiko Kuwajima is an employee of the Medical & Biological Laboratories Co., Ltd., Nagoya, Japan. The other authors declare that there are no conflicts of interest associated with the present study.

Informed consent

Informed consent was obtained from all patients, and the study was approved by the Ethics Committee of Chiba Cancer Center (no. 21-26) and Toho University School of Medicine (nos. 22-112 and 22-047). This clinical study has been registered in the UMIN Clinical Trials Registry (UMIN000014530).

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ushigome, M., Nabeya, Y., Soda, H. et al. Multi-panel assay of serum autoantibodies in colorectal cancer. Int J Clin Oncol 23, 917–923 (2018). https://doi.org/10.1007/s10147-018-1278-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1278-3

Keywords

Search

Navigation